UBS Group’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

UBS Group’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-40,890	Closed	-$10.4K	–	10380
2023 Q1	$10.4K	Buy	40,890 +24,900	+156%	+$22.5K	﹤0.01%	7581
2022 Q4	$18.9K	Buy	+15,990	New	+$33.6K	﹤0.01%	7710
2022 Q2	–	Sell	-3,292	Closed	-$17K	–	11417
2022 Q1	$17K	Sell	3,292 -1,077	-25%	-$4.89K	﹤0.01%	7704
2021 Q4	$27K	Buy	+4,369	New	+$39K	﹤0.01%	7520

UBS Group's PEAR Position: Q2 2023 in Review

UBS Group sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 40,890 shares — an estimated $10.4K sold.

UBS Group first reported a position in PEAR in Q4 2021 and held it in 4 quarters. The position peaked at $27K in Q4 2021. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

UBS Group reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
UBS Group sold 40,890 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $10.4K.
UBS Group first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 4 quarters.
UBS Group's Pear Therapeutics, Inc. Class A Common Stock position peaked at $27K in Q4 2021.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.